Boston Scientific Corp (XTER:BSX)
€ 86.5 -0.5 (-0.57%) Market Cap: 126.52 Bil Enterprise Value: 134.81 Bil PE Ratio: 74.93 PB Ratio: 6.45 GF Score: 79/100

Boston Scientific Corp Investor Update at TCT Transcript

Sep 18, 2022 / 01:00PM GMT
Lauren Tengler
Boston Scientific Corporation - Director of IR

Welcome, everyone, both here in the room and on the webcast today. We're excited to welcome our cardiology leadership team, but before we get to that, I'm going to go through some housekeeping items. First, we'll be providing forward-looking statements, so typical safe harbor and risk factors apply. Second, here are some of our regulatory and financial disclaimers. And with that, I'd like to hand it over to Joe Fitzgerald, Executive Vice President and President of Cardiology Group.

Joseph M. Fitzgerald
Boston Scientific Corporation - Executive VP & Group President of Cardiology

Well, that was quicker than I thought, but thank you, Lauren. Good morning, everybody. Thanks for joining us. We have the majority of our cardiology leadership team here with [Lance], who runs our coronary and structural components; Jim Cassidy runs our WATCHMAN franchise; and then the well-known Dr. Ian Meredith, who covers everything in cardiology. So again, thanks for joining.

I want to just give a

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot